Generex Launches New Corporate Website

WORCESTER, Mass., and TORONTO, April 5, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced it has launched its redesigned corporate website consistent with new management's drive to establish a focused and transparent approach to the development and approval of the Company's pipeline of diabetes and immunotherapeutic vaccine products.

(Logo:  https://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b )

Aside from a new look, the Company's website will continue to evolve, providing improved descriptions of products, technologies, scientific research in progress, trial results, and new corporate relationships as they unfold.  As management's strategic development plan for the Company is refined in the coming weeks and months, information will be highlighted on the website to keep stockholders fully informed as the June 8, 2011 Annual Meeting of the Generex stockholders approaches.

Investors will be able to review corporate performance information and view responses to questions from Generex's senior management.  Future plans also include enrichment of Generex's social media presence on Twitter (http://twitter.com/GenerexBiotech), Facebook (http://www.facebook.com/GenerexBiotechnology) and related social media sites.

The Company has two additional website properties that are of interest:  Antigen Express, Inc.'s (Generex's wholly-owned subsidiary) website (www.antigenexpress.com), and an information site that provides reference information to individuals and Healthcare Professionals who are involved, or wish to be involved, with the use of  Generex Oral-lyn™, the Company's proprietary buccal insulin spray product, under the USFDA's Treatment IND guidelines (www.generextxind.com).

Note that information and updates on Generex's clinical trials under the FDA can be found at www.clinicaltrials.gov (search Clinical Trials for the keyword "Generex").

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies.  Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).  The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  The Company's buccal insulin spray product, Generex Oral-lyn™ is in Phase III clinical trials at several sites around the world.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  Antigen Express has pioneered the use of specific CD4+ T helper stimulation in immunotherapy.  One of its platform technologies relies on inhibition of expression of the Ii protein.  Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T helper cells and prevents the further growth of cancer cells.  For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Safe Harbor Statement

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts.  Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not.  Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement.  No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements.  Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials.  Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency.  Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

SOURCE Generex Biotechnology Corporation